A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer

A Randomized Study of the Effect of Maintenance Therapy With Bevacizumab + Capecitabine Versus Bevacizumab Alone on Progression-free Survival in Patients With HER2-negative Metastatic Breast Cancer That Has Not Progressed During First-line Docetaxel Plus Bevacizumab Therapy

This randomized study will compare maintenance therapy with Avastin (bevacizumab) + Xeloda (capecitabine) versus Avastin alone, in patients with HER2-negative metastatic breast cancer who have not progressed during first-line therapy with docetaxel + Avastin. Eligible patients will receive up to 6 x 3 week cycles of treatment with Avastin (15 mg/mg IV on Day 1 of each cycle) + docetaxel (75-100 mg/m2 IV on Day 1 of each cycle). Those patients who do not progress will be randomized to 3 week cycles of either a) Avastin (15 mg/kg IV on Day 1 of each cycle) + Xeloda (1000 mg/m2 po bid on Days 1-14 of each cycle) or b) Avastin alone. Study treatment will continue until disease progression, unacceptable toxicity, patient request for withdrawal or end of study, and the target sample size is 100-500 individuals.

Study Overview

• Status: Completed
• Conditions: Breast Cancer
• Intervention / Treatment: Drug: bevacizumab [Avastin]; Drug: capecitabine [Xeloda]

• Study Type: Interventional
• Enrollment (Actual): 287
• Phase: Phase 3

Contacts and Locations

Study Locations

• Brazil
  • CE
    • Fortaleza, CE, Brazil, 60336-550
  • MG
    • Belo Horizonte, MG, Brazil, 30190-130
  • RJ
    • Rio de Janeiro, RJ, Brazil, 20560-120
  • RS
    • Ijui, RS, Brazil, 98700-000
    • Porto Alegre, RS, Brazil, 90035-003
  • SP
    • Jau, SP, Brazil, 17210-080
    • Santo Andre, SP, Brazil, 09060-650
    • Sao Paulo, SP, Brazil, 01246-000
    • Sao Paulo, SP, Brazil, 08270-070
• China
  • Beijing, China, 100021
  • Beijing, China, 100071
  • Beijing, China, 100853
  • Hangzhou, China, 310022
  • Hangzhou, China, 310009
  • Shanghai, China, 200032
• Egypt
  • Alexandria, Egypt, 11737
  • Cairo, Egypt, 11796
• France
  • Amiens, France, 80090
  • Angers, France, 49933
  • Besancon, France, 25030
  • Bobigny, France, 93009
  • Dijon, France, 21079
  • Hyeres, France, 83400
  • Le Coudray, France, 28630
  • Lille, France, 59000
  • Paris, France, 75970
  • Paris, France, 75231
  • Perigueux, France, 24000
  • Rodez, France, 12027
  • St Priest En Jarez, France, 42271
  • Strasbourg, France, 67010
• Hong Kong
  • Hong Kong, Hong Kong
  • Hong Kong, Hong Kong, 852
• India
  • Bangalore, India, 560027
  • Hyderabad, India, 500034
  • Mumbai, India, 400012
  • Mumbai, India, 400020
  • New Delhi, India, 110 060
  • New Delhi, India, 110085
• Italy
  • Campania
    • Napoli, Campania, Italy, 80131
  • Friuli-Venezia Giulia
    • Trieste, Friuli-Venezia Giulia, Italy, 34100
  • Liguria
    • Genova, Liguria, Italy, 16132
  • Lombardia
    • Saronno, Lombardia, Italy, 21047
  • Puglia
    • Brindisi, Puglia, Italy, 72100
  • Toscana
    • Antella (FI), Toscana, Italy, 50011
• Poland
  • Bydgoszcz, Poland, 85-796
  • Wroclaw, Poland, 53-413
• Saudi Arabia
  • Dammam, Saudi Arabia, 31444
  • Jeddah, Saudi Arabia, 21497
  • Jeddah, Saudi Arabia, 21589
• Spain
  • Jaen, Spain, 23007
  • Malaga, Spain, 29010
  • Toledo, Spain, 45004
  • Valencia, Spain, 46026
  • Alicante
    • Alcoy, Alicante, Spain, 03804
  • Barcelona
    • Sabadell, Barcelona, Barcelona, Spain, 08208
  • Ciudad Real
    • Alcazar de S. Juan, Ciudad Real, Spain, 13600
  • Vizcaya
    • Barakaldo, Vizcaya, Spain, 48903
• Turkey
  • Ankara, Turkey, 06500
  • Ankara, Turkey, 06800
  • Antalya, Turkey, 07070
  • Istanbul, Turkey, 34000
  • Sıhhiye, ANKARA, Turkey, 06100

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• adult patients, >=18 years of age;
• HER2-negative metastatic breast cancer
• candidates for taxane-based chemotherapy;
• ECOG performance status of 0 or 1.

Exclusion Criteria:

• previous chemotherapy for metastatic breast cancer;
• prior adjuvant/neo-adjuvant chemotherapy within 6 months prior to study;
• prior radiotherapy for treatment of metastatic disease;
• chronic daily treatment with aspirin (325 mg/day) or clopidogrel(>75mg/day).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Avastin (bevacizumab)	Drug: bevacizumab [Avastin]; 15 mg/kg iv on day 1 of each 3 week cycle (maintenance phase)
EXPERIMENTAL: Avastin (bevacizumab) + Xeloda (capecitabine)	Drug: bevacizumab [Avastin]; 15 mg/kg iv on day 1 of each 3 week cycle (maintenance phase); Drug: capecitabine [Xeloda]; 1000 mg/m2 po bid on days 1-14 of each 3 week cycle (maintenance phase)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Disease Progression or Death (Maintenance Phase Data Cutoff October 4, 2013)	Progression Free Survival (PFS) was defined as the time from first study drug dosing (during the maintenance treatment phase) to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST). Progressive Disease (PD) was defined as a 20 percent (%) or greater increase in the sum of the Longest Diameter (LD) of the target lesions taking as reference the smallest sum LD recorded or appearance of new lesions.	Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years
Progression Free Survival (Maintenance Phase Data Cutoff October 4, 2013)	PFS was defined as the time from first study drug dosing to the first documented disease progression or death, whichever occurred first.Time to progression was defined as the time from randomization to the first documented disease progression defined per RECIST 1.0 criteria. Participants without an event at data cut-off or who were withdrawn from the study without documented progression were censored at the date of the last tumor assessment when the participant was known to be progression free. Participants who took other non-protocol anti-cancer drugs while being on study medication, and who were still event free were censored on the date of first dose of the anti-cancer drug. Participants without post-randomization tumor assessments but alive were censored at the time of randomization. Participants without post-randomization assessments, who died after randomization were considered to have the PFS event at date of death. Kaplan-Meier estimation was used for median time to PFS	Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Best Overall Confirmed Objective Response of CR or PR Per RECIST 1.0 (Maintenance Phase Data Cutoff October 4, 2013)	Objective Response was determined by the investigator using modified RECIST criteria, Version 1.0. An objective response was a complete or partial overall confirmed response as determined by investigators. CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as greater than or equal to (≥) 30 % decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. Progressive disease (PD) was defined as 20% increase in the sum of the longest diameter of target lesions and SD was defined as small changes that do not meet above criteria. Pearson-Clopper one-sample method was used for Confidence intervals (CIs).	Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years
Percentage of Participants With Clinical Benefit (CR, PR and SD) Per RECIST 1.0 (Data Cutoff October 4, 2013)	CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as ≥ 30 % decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. SD was defined as small changes that do not meet above criteria.	Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years
Percentage of Participants Who Died (Maintenance Phase Data Cutoff October 4, 2013)		Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years
Overall Survival (Maintenance Phase Data Cutoff October 4, 2013)	Duration of Overall Survival (OS) was defined as the time from randomization to death of any cause. The OS data for participants for whom no death was captured in the clinical database were censored at the last time they were known to be alive. Kaplan Meier estimation was used to determine OS.	Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years
Percentage of Participants Expected to Be Alive After 1 and 2 Years on Treatment (Maintenance Phase Data Cutoff October 4, 2013)	Probability of being alive after 1 and 2 years on treatment with 95% CIs was calculated using Kaplan Meier approach with LOGLOG transformation.	Years 1 and 2
Percentage Of Participants With PD or Death Due to PD (Maintenance Phase Data Cutoff October 4, 2013)	PD was defined per RECIST 1.0 as 20% increase in the sum of the longest diameter of target lesions.	Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013
Time To Progression (Maintenance Phase Data Cutoff October 4, 2013)	Time to Progression was defined as the time from randomization to the first documented disease progression (using investigator assessments of disease progression by RECIST 1.0). PD was defined as 20% increase in the sum of the longest diameter of target lesions.	Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013
Quality of Life Assessed As Change From Baseline in Global Health Status Using The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - 30 (EORTC QLQ - C30) (Maintenance Phase Data Cutoff October 4, 2013)	The EORTC QLQ-C30 incorporates 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social); 9 symptom scales (fatigue, pain, nausea and vomiting, dyspnoea, insomnia, appetite loss, constipation, diarrhea and financial difficulties); and a global health and quality-of-life scale. Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms. The change in global health status was determined to be the difference in values at baseline and each specific visit. The term ''baseline'' refers to the time of randomization to the maintenance phase.	Baseline, Randomization and Cycles 3, 6, 9 and 12
Percentage of Participants With Best Overall Confirmed Objective Response of CR or PR Per RECIST 1.0 (Initial Treatment Phase)	Objective Response was determined by the investigator using RECIST criteria, Version 1.0. An objective response was a complete or partial overall confirmed response as determined by investigators. CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as ≥ 30% decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. Pearson-Clopper one-sample method was used for CI.	Screening and at the end of every third cycle until randomization for an average of 18 weeks
Percentage of Participants With Clinical Benefit (CR, PR and SD) Per RECIST 1.0 (Initial Treatment Phase)	CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as ≥30% decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. SD was defined as small changes that do not meet above criteria.	Screening and at the end of every third cycle until randomization for an average of 18 weeks

Collaborators and Investigators

• Sponsor: Hoffmann-La Roche

Publications and helpful links

General Publications

• Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga JY, Gupta V, Costa R, Srock S, de Ducla S, Freudensprung U, Mustacchi G. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1351-60. doi: 10.1016/S1470-2045(14)70444-9. Epub 2014 Sep 28.

Study record dates

Study Major Dates

• Study Start: July 1, 2009
• Primary Completion (ACTUAL): June 1, 2014
• Study Completion (ACTUAL): June 1, 2014

Study Registration Dates

• First Submitted: June 16, 2009
• First Submitted That Met QC Criteria: June 25, 2009
• First Posted (ESTIMATE): June 26, 2009

Study Record Updates

• Last Update Posted (ESTIMATE): March 3, 2015
• Last Update Submitted That Met QC Criteria: March 2, 2015
• Last Verified: March 1, 2015

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Antineoplastic Agents, Immunological; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Capecitabine; Bevacizumab
• Other Study ID Numbers: MO22223; 2008-006872-31